6gee - Revision history

OCA at 12:41, 6 November 2024

2024-11-06T12:41:00Z

← Older revision		Revision as of 12:41, 6 November 2024
Line 1:		Line 1:

	==TEAD4 (216-434);E263A COMPLEXED WITH YAP PEPTIDE (60-100); S94A AND MYRISTOATE (COVALENTLY BOUND) AT 1.96A (P41212 CRYSTAL FORM); MYRISTOYLATION WAS DONE BY ADDING MYR-COA==		==TEAD4 (216-434);E263A COMPLEXED WITH YAP PEPTIDE (60-100); S94A AND MYRISTOATE (COVALENTLY BOUND) AT 1.96A (P41212 CRYSTAL FORM); MYRISTOYLATION WAS DONE BY ADDING MYR-COA==
	<StructureSection load='6gee' size='340' side='right' caption='[[6gee]], [[Resolution\|resolution]] 1.96Å' scene=''>		<StructureSection load='6gee' size='340' side='right'caption='[[6gee]], [[Resolution\|resolution]] 1.96Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
	<table><tr><td colspan='2'>[[6gee]] is a 2 chain structure with sequence from [~~http~~://en.wikipedia.org/wiki/~~Human Human~~]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6GEE OCA]. For a <b>guided tour on the structure components</b> use [~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=6GEE FirstGlance]. <br>		<table><tr><td colspan='2'>[[6gee]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6GEE OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6GEE FirstGlance]. <br>
	</td></tr><tr id='~~ligand~~'><td class="sblockLbl"><b>[[~~Ligand~~\|~~Ligands~~:]]</b></td><td class="sblockDat"~~><scene name~~=~~'pdbligand=MYR:MYRISTIC+ACID'>MYR</scene~~></td></tr>		</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 1.96Å</td></tr>
	<tr id='~~NonStdRes~~'><td class="sblockLbl"><b>[[~~Non-Standard_Residue~~\|~~NonStd Res~~:]]</b></td><td class="sblockDat"><scene name='pdbligand=ACE:ACETYL+GROUP'>ACE</scene><~~/td></tr>~~		<tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=ACE:ACETYL+GROUP'>ACE</scene>, <scene name='pdbligand=MYR:MYRISTIC+ACID'>MYR</scene></td></tr>
	~~<tr id~~='~~related'><td class~~=~~"sblockLbl"><b>[[Related_structure\|Related~~:~~]]</b></td><td class="sblockDat">[[6ge3\|6ge3]], [[6ge4\|6ge4]], [[6ge5\|6ge5]], [[6ge6\|6ge6]], [[6gec\|6gec]]</td></tr>~~		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6gee FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6gee OCA], [https://pdbe.org/6gee PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6gee RCSB], [https://www.ebi.ac.uk/pdbsum/6gee PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6gee ProSAT]</span></td></tr>
	~~<tr id='gene~~'>~~<td class="sblockLbl"><b>[[Gene\|Gene:]]~~</b>~~</td><td class="sblockDat">TEAD4, RTEF1, TCF13L1, TEF3 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])~~</td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=6gee FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6gee OCA], [~~http~~://pdbe.org/6gee PDBe], [~~http~~://www.rcsb.org/pdb/explore.do?structureId=6gee RCSB], [~~http~~://www.ebi.ac.uk/pdbsum/6gee PDBsum], [~~http~~://prosat.h-its.org/prosat/prosatexe?pdbcode=6gee ProSAT]</span></td></tr>
	</table>		</table>
	== Function ==		== Function ==
	[~~[http~~://www.uniprot.org/uniprot/TEAD4_HUMAN TEAD4_HUMAN]] Transcription factor which plays a key role in the Hippo signaling pathway, a pathway involved in organ size control and tumor suppression by restricting proliferation and promoting apoptosis. The core of this pathway is composed of a kinase cascade wherein MST1/MST2, in complex with its regulatory protein SAV1, phosphorylates and activates LATS1/2 in complex with its regulatory protein MOB1, which in turn phosphorylates and inactivates YAP1 oncoprotein and WWTR1/TAZ. Acts by mediating gene expression of YAP1 and WWTR1/TAZ, thereby regulating cell proliferation, migration and epithelial mesenchymal transition (EMT) induction. Binds specifically and non-cooperatively to the Sph and GT-IIC 'enhansons' (5'-GTGGAATGT-3') and activates transcription. Binds to the M-CAT motif.<ref>PMID:18579750</ref> <ref>PMID:19324877</ref> [[http://www.uniprot.org/uniprot/YAP1_HUMAN YAP1_HUMAN]] Transcriptional regulator which can act both as a coactivator and a corepressor and is the critical downstream regulatory target in the Hippo signaling pathway that plays a pivotal role in organ size control and tumor suppression by restricting proliferation and promoting apoptosis. The core of this pathway is composed of a kinase cascade wherein STK3/MST2 and STK4/MST1, in complex with its regulatory protein SAV1, phosphorylates and activates LATS1/2 in complex with its regulatory protein MOB1, which in turn phosphorylates and inactivates YAP1 oncoprotein and WWTR1/TAZ. Plays a key role to control cell proliferation in response to cell contact. Phosphorylation of YAP1 by LATS1/2 inhibits its translocation into the nucleus to regulate cellular genes important for cell proliferation, cell death, and cell migration. The presence of TEAD transcription factors are required for it to stimulate gene expression, cell growth, anchorage-independent growth, and epithelial mesenchymal transition (EMT) induction. Isoform 2 and isoform 3 can activate the C-terminal fragment (CTF) of ERBB4 (isoform 3).<ref>PMID:12807903</ref> <ref>PMID:17974916</ref> <ref>PMID:18579750</ref> <ref>PMID:18158288</ref> <ref>PMID:18280240</ref> <ref>PMID:21364637</ref>		[https://www.uniprot.org/uniprot/TEAD4_HUMAN TEAD4_HUMAN] Transcription factor which plays a key role in the Hippo signaling pathway, a pathway involved in organ size control and tumor suppression by restricting proliferation and promoting apoptosis. The core of this pathway is composed of a kinase cascade wherein MST1/MST2, in complex with its regulatory protein SAV1, phosphorylates and activates LATS1/2 in complex with its regulatory protein MOB1, which in turn phosphorylates and inactivates YAP1 oncoprotein and WWTR1/TAZ. Acts by mediating gene expression of YAP1 and WWTR1/TAZ, thereby regulating cell proliferation, migration and epithelial mesenchymal transition (EMT) induction. Binds specifically and non-cooperatively to the Sph and GT-IIC 'enhansons' (5'-GTGGAATGT-3') and activates transcription. Binds to the M-CAT motif.<ref>PMID:18579750</ref> <ref>PMID:19324877</ref>
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
	== Publication Abstract from PubMed ==		== Publication Abstract from PubMed ==
Line 25:		Line 23:
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
	[[Category: ~~Human~~]]		[[Category: Homo sapiens]]
	[[Category: ~~Kallen, J~~]]		[[Category: Large Structures]]
	[[Category: ~~Co-activator complex]]~~		[[Category: Kallen J]]
	~~[[Category: Protein-protein interaction]]~~
	~~[[Category: Transcription~~]]

OCA at 07:18, 31 October 2018

2018-10-31T07:18:14Z

← Older revision		Revision as of 07:18, 31 October 2018
Line 3:		Line 3:
	<StructureSection load='6gee' size='340' side='right' caption='[[6gee]], [[Resolution\|resolution]] 1.96Å' scene=''>		<StructureSection load='6gee' size='340' side='right' caption='[[6gee]], [[Resolution\|resolution]] 1.96Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
	<table><tr><td colspan='2'>[[6gee]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6GEE OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6GEE FirstGlance]. <br>		<table><tr><td colspan='2'>[[6gee]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6GEE OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6GEE FirstGlance]. <br>
	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=MYR:MYRISTIC+ACID'>MYR</scene></td></tr>		</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=MYR:MYRISTIC+ACID'>MYR</scene></td></tr>
	<tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue\|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=ACE:ACETYL+GROUP'>ACE</scene></td></tr>		<tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue\|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=ACE:ACETYL+GROUP'>ACE</scene></td></tr>
	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[6ge3\|6ge3]], [[6ge4\|6ge4]], [[6ge5\|6ge5]], [[6ge6\|6ge6]], [[6gec\|6gec]]</td></tr>		<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[6ge3\|6ge3]], [[6ge4\|6ge4]], [[6ge5\|6ge5]], [[6ge6\|6ge6]], [[6gec\|6gec]]</td></tr>
			<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">TEAD4, RTEF1, TCF13L1, TEF3 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6gee FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6gee OCA], [http://pdbe.org/6gee PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6gee RCSB], [http://www.ebi.ac.uk/pdbsum/6gee PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6gee ProSAT]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6gee FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6gee OCA], [http://pdbe.org/6gee PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6gee RCSB], [http://www.ebi.ac.uk/pdbsum/6gee PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6gee ProSAT]</span></td></tr>
	</table>		</table>
Line 24:		Line 25:
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
			[[Category: Human]]
	[[Category: Kallen, J]]		[[Category: Kallen, J]]
	[[Category: Co-activator complex]]		[[Category: Co-activator complex]]
	[[Category: Protein-protein interaction]]		[[Category: Protein-protein interaction]]
	[[Category: Transcription]]		[[Category: Transcription]]

OCA at 19:56, 19 September 2018

2018-09-19T19:56:26Z

@@ Line 1: / Line 1: @@
-The entry 6gee is ON HOLD  until Paper Publication
+==TEAD4 (216-434);E263A COMPLEXED WITH YAP PEPTIDE (60-100); S94A AND MYRISTOATE (COVALENTLY BOUND) AT 1.96A (P41212 CRYSTAL FORM); MYRISTOYLATION WAS DONE BY ADDING MYR-COA==
-Authors: Kallen, J.
+Adaptation of the bound intrinsically disordered protein YAP to mutations at the YAP:TEAD interface.,Mesrouze Y, Bokhovchuk F, Izaac A, Meyerhofer M, Zimmermann C, Fontana P, Schmelzle T, Erdmann D, Furet P, Kallen J, Chene P Protein Sci. 2018 Jul 29. doi: 10.1002/pro.3493. PMID:30058229<ref>PMID:30058229</ref>
-Description: TEAD4 (216-434);E263A COMPLEXED WITH YAP PEPTIDE (60-100); S94A AND MYRISTOATE (COVALENTLY BOUND) AT 1.96A (P41212 CRYSTAL FORM); MYRISTOYLATION WAS DONE BY ADDING MYR-COA
+From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
-[[Category: Unreleased Structures]]
+</div>
 [[Category: Kallen, J]]

OCA at 05:03, 9 May 2018

2018-05-09T05:03:13Z

← Older revision		Revision as of 05:03, 9 May 2018
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

	The entry 6gee is ON HOLD		The entry 6gee is ON HOLD until Paper Publication

	Authors: Kallen, J.		Authors: Kallen, J.

OCA: Protected "6gee" [edit=sysop:move=sysop]

2018-05-02T06:56:27Z

Protected "6gee" [edit=sysop:move=sysop]

← Older revision	Revision as of 06:56, 2 May 2018
(No difference)

OCA: New page: '''Unreleased structure''' The entry 6gee is ON HOLD Authors: Kallen, J. Description: TEAD4 (216-434);E263A COMPLEXED WITH YAP PEPTIDE (60-100); S94A AND MYRISTOATE (COVALENTLY BOUND) ...

2018-05-02T06:56:25Z

New page: '''Unreleased structure''' The entry 6gee is ON HOLD Authors: Kallen, J. Description: TEAD4 (216-434);E263A COMPLEXED WITH YAP PEPTIDE (60-100); S94A AND MYRISTOATE (COVALENTLY BOUND) ...

New page

'''Unreleased structure'''

The entry 6gee is ON HOLD

Authors: Kallen, J.

Description: TEAD4 (216-434);E263A COMPLEXED WITH YAP PEPTIDE (60-100); S94A AND MYRISTOATE (COVALENTLY BOUND) AT 1.96A (P41212 CRYSTAL FORM); MYRISTOYLATION WAS DONE BY ADDING MYR-COA
[[Category: Unreleased Structures]]
[[Category: Kallen, J]]